Santa Clara, Calif., Aug. 25, 2016 — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has announced the appointment of Amar Thyagarajan, Ph.D., and Sandeep Sinha, Ph.D., to its team.
Thyagarajan joins CrownBio as the associate director of product marketing and strategy. With extensive experience in bringing new products to market, he is responsible for the strategic and scientific marketing of CrownBio’s cardiovascular and metabolic disease (CVMD) portfolio.
Thyagarajan brings extensive scientific and senior product management experience with genetically engineered models used in neuroscience and CVMD drug discovery and safety and toxicology studies. He earned his doctorate in neuroscience at the State University of New York at Albany, followed by a postdoctoral fellowship at the Massachusetts Institute of Technology in neuroscience and chemical biology.
“With Amar’s acumen for developing market strategies, he will enhance our marketing communications and presence for our growing line of CVMD models and services to support drug development,” said Laurie Heilmann, senior vice president of global strategy, marketing and business development at CrownBio.
Well-recognized in the industry, Sinha is joining the team as scientific director and is responsible for providing direction to CrownBio’s technical teams to build better partnerships with clients to execute successful CVMD programs.
Prior to joining CrownBio, Sinha worked at Eli Lilly as a medical science liaison for diabetes and cardiovascular disease. He received his doctorate in biochemistry from Aligarh Muslim University, India, served as a postdoctoral researcher at the University of Pittsburgh Medical Center in the endocrine division and held research positions at several notable universities.
“CrownBio is committed to hiring experienced and knowledgeable industry leaders to advance our CVMD services to benefit our clients, and we are pleased to add these talented individuals to our team,” said Heilmann.
For more information on CrownBio’s growing CVMD portfolio, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.